尤瑞克林对2型糖尿病合并急性脑梗死患者的临床有效性研究

Study on the Clinical Effectiveness of Urekelin in Patients with Type 2 Diabetes Mellitus Complicated with Acute Cerebral Infarction

目的探讨对2型糖尿病伴有急性脑梗死患者给予尤瑞克林治疗后获得的临床效果。方法方便选取2020年1月—2021年6月收治的106例2型糖尿病伴有急性脑梗死患者进行治疗研究,随机分为参照组(采用脑血管病基础药物完成对应治疗)和研究组(采用脑血管病基础药物+尤瑞克林药物完成对应治疗),各53例。比较两组患者ADL评分、NIHSS评分、血糖水平以及不良事件情况。结果治疗前,研究组日常生活能力量表(ADL)评分(35.13±5.06)分、神经功能缺损评分(NIHSS)评分(11.26±5.22)分同参照组比较,差异无统计学意义(t=0.874、0.343,P>0.05);治疗后,研究组ADL评分(62.32±5.29)分、NIHSS评分(5.65±1.04)分优于参照组,差异有统计学意义(t=6.008、5.769,P<0.05);治疗前,研究组空腹血糖水平(5.49±1.03)mmol/L同参照组比较,差异无统计学意义(t=0.298,P>0.05);治疗后,研究组空腹血糖(5.59±1.03)mmol/L、餐后2 h血糖(7.69±2.25)mmol/L同参照组比较,差异无统计学意义(t=0.541、0.455,P>0.05);研究组出血性脑梗死患者1例,分析患者因为肺部感染、高龄以及头孢类抗生素使用,导致凝血功能受到影响;一过性低血压患者1例,分析因为过快静脉滴注速度造成,将滴注速度纠正后,获得缓解。参照组未出现不良事件。结论有效应用尤瑞克林药物后,患者日常生活能力获得显著提高,神经功能缺损得到明显改善,治疗安全性显著,可促进2型糖尿病伴有急性脑梗死患者整体用药水平,预后水平显著提升。

Objective To investigate the clinical effects of ureklin in patients with type 2 diabetes and acute cerebral infarction.Methods A total of 106 patients with type 2 diabetes and acute cerebral infarction who were admitted from January 2020 to June 2021 were conveniently selected for treatment research.Randomly divided into the reference group(using basic drugs for cerebrovascular disease to complete the corresponding treatment)and the study group(using basic drugs for cerebrovascular disease+the ureklin drug to complete the corresponding treatment),with 53 cases in each.The activities of daily living(ADL)score,neurological deficit score(NIHSS)score,blood glucose level and adverse events of the two groups were compared.Results Before treatment,there was no statistically significant difference in ADL score(35.13±5.06)points and NIHSS score(11.26±5.22)points between the study group and the reference group(t=0.874,0.343,P>0.05);after treatment,the scores of ADL(62.32±5.29)points and NIHSS(5.65±1.04)points in the study group were better than those in the reference group,and the difference was statistically significant(t=6.008,5.769,P<0.05);before treatment,there was no statistically significant difference in fasting blood glucose level(5.49±1.03)mmol/L between the study group and the reference group(t=0.298,P>0.05);after treatment,there was no statistically significant difference in fasting blood glucose(5.59±1.03)mmol/L and postprandial blood glucose(7.69±2.25)mmol/L between the study group and the reference group(t=0.541,0.455,P>0.05);one patient with hemorrhagic cerebral infarction in the study group was analyzed.The coagulation function was affected due to pulmonary infection,old age and the use of cephalosporins;one case of transient hypotension was analyzed because of too fast intravenous drip speed.After correcting the drip speed,it was relieved.There were no adverse events in the reference group.Conclusion After the effective application of Yuri Klein,the daily living ability of patients was significantly improved,the neurological deficit was improved significantly,the safety of treatment was significant,and the overall medication level and prognosis of type 2 diabetes patients with acute cerebral infarction were significantly improved.